Here’s why the Recce (ASX:RCE) share price is climbing today

The company’s shares are set to finish today on a high note.

| More on:
a group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.

Image source: Getty Images

Key Points

  • The Recce share price is up 3.85% to $1.35
  • An independent safety committee has cleared stronger dosing of Recce 327
  • Trial subjects are expected to be recruited sometime this week

The Recce Pharmaceuticals Ltd (ASX: RCE) share price is on the move today. This comes after the pharmaceutical company reported further positive data from the clinical trial of its antibiotic candidate, Recce 327.

At the time of writing, the biotechnology company’s shares are swapping hands for $1.35, up 3.85%. In comparison, the All Ordinaries (ASX: XAO) is down 0.13% to 7,729.6 points.

Recce moves ahead with clinical trial

Investors are snapping up Recce shares after the company reported positive safety results in a trial for its broad-spectrum antibiotic drug, Recce 327.

The phase I trial assessed the safety and efficacy of Recce 327 against infectious bacteria on burn wounds in patients.

According to its announcement, the company advised that 7 healthy male patients have received 150mg of Recce 327 intravenously. It said this second group of subjects appears to be safe and well, tolerating the level of dosage.

An earlier first study cohort had been administered 50mg of the drug.

Based on the above data, an independent safety committee has approved a threefold increase in the dose for the third study cohort. This will see between 7 to 10 healthy volunteers being administered up to 500mg of Recce 327.

The subjects are expected to be recruited this week and dosed at Adelaide’s CMAX clinical trial facility.

Recce CEO James Graham commented:

We are pleased to see R327 (150mg) successfully tolerated as an intravenous infusion in Cohort Two subjects. Having successfully cleared two dosing levels (50mg and 150mg) we look forward to embarking upon this next significant milestone.

Recce share price summary

Recce is involved in the advancement of synthetic antibodies designed to address the global health challenge of antibiotic-resistant superbugs. The medical company’s flagship drug Recce 327 is being developed to treat blood infections and sepsis.

Over the past 12 months, the Recce share price has accelerated by almost 30%. These gains have come year to date following the positive safety data from its phase 1 clinical trial.

Based on today’s price, Recce presides a market capitalisation of roughly $235 million, with approximately 174 million shares on issue.

Should you invest $1,000 in Recce right now?

Before you consider Recce, you'll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Recce wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of January 13th 2022

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Three Archer Materials scientists wearing white coats and blue gloves dance together in their lab after making a discovery
Growth Shares

Why CSL shares are ‘going to deliver’ in 2022: fund manager

Quality growth companies can perform well even in an era of rising interest rates.

Read more »

a group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
Healthcare Shares

Incannex share price pops 9% on FDA news

The medicinal cannabis drug development company came out with some positive developments from its FDA meeting...

Read more »

Two medical researchers in white coats collaborate over a computer screen of data in a medical research laboratory
Broker Notes

Where next for the CSL share price?

CSL shares could be heading higher according to one leading broker...

Read more »

A telehealth doctor at her desk.
Healthcare Shares

Why is the Ramsay share price smashing the ASX 200 on Monday?

Ramsay shares are off to a positive start today.

Read more »

a doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.
Healthcare Shares

What’s going on with the Polynovo share price today?

The strong start has dissipated for Polynovo shares.

Read more »

a doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.
Healthcare Shares

Virtus share price holds steady despite 30% earnings fall

Shareholders are staying loyal with a looming acquisition.

Read more »

a medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.
Earnings Results

Avita Medical share price tumbles 7% on declining Q1 revenue

The ASX healthcare share saw its net loss for the quarter increase 58% year-on-year.

Read more »

ASX share price movement represented by doctor pressing digitised screen with array of icons including one entitled health insurance
Healthcare Shares

Own Medibank shares? Here’s what to watch over the coming months

What are the key dates for Medibank in 2022?

Read more »